Here’s What Piper Sandler Thinks About Boston Scientific Corp (BSX) Now

Why It Matters

The bullish stance signals strong demand for cardiac‑device innovations, positioning BSX for sustained revenue acceleration and influencing investor sentiment in the med‑tech sector.

Key Takeaways

• Piper Sandler keeps Overweight rating on BSX after Watchman data.
• Watchman sales projected to rise 20% yearly, adding 200 bps growth.
• 2025 net sales hit $20 billion, EPS $3.06, 19.9% increase.
• BSX forecasts at least 10.5% topline growth in 2026.
• Over 59 million global patients could benefit from Watchman implant.

Pulse Analysis

Boston Scientific’s Watchman device has become a focal point in the convergence of cardiovascular therapy and artificial intelligence. The Champion‑AF study, a pivotal trial evaluating Watchman as a first‑line stroke‑prevention option for atrial fibrillation, confirmed the implant’s safety and efficacy across primary and secondary endpoints. This validation not only bolsters clinician confidence but also aligns with the broader trend of AI‑driven patient selection and outcome monitoring, positioning the device as a benchmark for data‑rich medical technologies.

From a financial perspective, Piper Sandler’s reaffirmation of an Overweight rating reflects confidence in the device’s revenue trajectory. A projected 20% annual growth rate for Watchman sales translates into an estimated 200‑basis‑point lift to Boston Scientific’s overall revenue growth, a material contribution given the company’s $20 billion 2025 sales base. The firm’s adjusted EPS of $3.06, up from $2.51 a year earlier, underscores the profitability of its high‑margin device portfolio, while the forecasted 10.5% topline expansion in 2026 signals continued momentum.

The broader market implications are significant. With more than 59 million individuals worldwide living with atrial fibrillation, the addressable market for left‑atrial appendage closure devices is vast and still expanding. Competitors are racing to integrate AI analytics into device design and post‑implant care, but Boston Scientific’s early success and strong analyst backing give it a competitive edge. Investors should monitor adoption rates, reimbursement landscapes, and potential AI enhancements that could further differentiate Watchman, as these factors will shape the company’s growth trajectory in the evolving med‑tech ecosystem.